Objective-Increased protein SUMOylation (small ubiquitin-related modifier [SUMO]) provides protection from cellular stress, including oxidative stress, but the mechanisms involved are incompletely understood. The NADPH oxidases (Nox) are a primary source of reactive oxygen species (ROS) and oxidative stress, and thus our goal was to determine whether SUMO regulates NADPH oxidase activity. Methods and Results-Increased expression of SUMO1 potently inhibited the activity of Nox1 to Nox5. In contrast, inhibition of endogenous SUMOylation with small interfering RNA to SUMO1 or ubiquitin conjugating enzyme 9 or with the inhibitor anacardic acid increased ROS production from human embryonic kidney-Nox5 cells, human vascular smooth muscle cells, and neutrophils. The suppression of ROS production was unique to SUMO1, and it required a C-terminal diglycine and the SUMO-specific conjugating enzyme ubiquitin conjugating enzyme 9. SUMO1 did not modify intracellular calcium or Nox5 phosphorylation but reduced ROS output in an isolated enzyme assay, suggesting direct effects of SUMOylation on enzyme activity. However, we could not detect the presence of SUMO1 conjugation on Nox5 using a variety of approaches. Moreover, the mutation of more than 17 predicted and conserved lysine residues on Nox5 did not alter the inhibitory actions of SUMO1. Conclusion-Together, these results suggest that SUMO is an important regulatory mechanism that indirectly represses the production of ROS to ameliorate cellular stress. Key Words: endothelium Ⅲ reactive oxygen species Ⅲ signal transduction Ⅲ stress Ⅲ vascular biology C ontrol over protein function in eukaryotes can be achieved via covalent posttranslational modifications, such as phosphorylation, methylation, acetylation, and ubiquitylation. The small ubiquitin-related modifier (SUMO) family of proteins is a more recently discovered posttranslational modification. 1 There are 4 SUMO genes (SUMO1 to SUMO4), which encode small proteins approximately 12 kDa in size that are distantly related to ubiquitin (Ϸ20%). The attachment of SUMO to target proteins occurs in a manner analogous to ubiquitylation but uses different enzymes. The SUMO proteins are first cleaved at their C terminus to expose a diglycine, activated by E1 enzymes, transferred to the SUMO-specific conjugating enzyme ubiquitin conjugating enzyme 9 (UBC9) (E2), and then attached to lysine residues of substrate proteins via an E3 ligase. 2 Cellular stress arising from imbalances in osmolarity, temperature, genotoxic metabolites, and, in particular, reactive oxygen species (ROS) is a robust stimulus for protein SUMOylation. 3, 4 SUMOylation is widely regarded as a protective mechanism, and loss of SUMO conjugation reduces cell and organism viability. 5, 6 
ontrol over protein function in eukaryotes can be achieved via covalent posttranslational modifications, such as phosphorylation, methylation, acetylation, and ubiquitylation. The small ubiquitin-related modifier (SUMO) family of proteins is a more recently discovered posttranslational modification. 1 There are 4 SUMO genes (SUMO1 to SUMO4), which encode small proteins approximately 12 kDa in size that are distantly related to ubiquitin (Ϸ20%). The attachment of SUMO to target proteins occurs in a manner analogous to ubiquitylation but uses different enzymes. The SUMO proteins are first cleaved at their C terminus to expose a diglycine, activated by E1 enzymes, transferred to the SUMO-specific conjugating enzyme ubiquitin conjugating enzyme 9 (UBC9) (E2), and then attached to lysine residues of substrate proteins via an E3 ligase. 2 Cellular stress arising from imbalances in osmolarity, temperature, genotoxic metabolites, and, in particular, reactive oxygen species (ROS) is a robust stimulus for protein SUMOylation. 3, 4 SUMOylation is widely regarded as a protective mechanism, and loss of SUMO conjugation reduces cell and organism viability. 5, 6 The overproduction of ROS and subsequent oxidative stress has been implicated in a number of pathological states, including cardiovascular disease, cancer, and inflammation. [7] [8] [9] The NA-DPH oxidases (Nox) are a major source of ROS and oxidative stress in mammalian cells. 10 The Nox family consists of 7 members-Nox1 to Nox5, Duox1, and Duox2-and are used in a number of important physiological roles, including host defense, cellular signaling, synthesis of thyroid hormone, and formation of otoconia. 11 The Nox enzymes are transmembrane oxidoreductases that span the membrane 6 times and contain 2 centrally coordinated heme residues and C-terminal cytoplasmic regions for binding flavin adenine dinucleotide and NADPH. 12 The activity of Nox1 to Nox3 is tightly controlled by the binding of regulatory proteins, such as p22 phox, p47phox, p67phox, and the organizers NoxO1 and NoxA1. 11, 13 The mechanisms controlling the activity of Nox4 remain poorly understood, and it is thought to constitutively produce hydrogen peroxide. 14 In contrast, the regulation of Nox5 is unique among the Nox isoforms in that it is calcium dependent and does not require the presence of cytosolic subunits for superoxide production. 15 ROS can alter the balance of signaling pathways by inactivating protein phosphatases, 16 modify protein structure and activity, 17 and react avidly with nitric oxide to reduce its biological effects. 18 Although we have gained considerable knowledge on the mechanisms controlling the activation of Nox enzymes, comparatively little is known about the mechanisms that limit or inhibit Nox activity and reduce ROS production.
Recent publications have intimated a close relationship between SUMOylation and ROS. Cellular stresses such as heat shock and osmotic and high oxidative stress (H 2 O 2 ) enhance SUMOylation. 3, 19 Elevated H 2 O 2 production in diabetes increases the SUMOylation of extracellular-signalregulated kinases-5 and promotes endothelial dysfunction, 20 and the ability of ROS to influence protein SUMOylation is concentration dependent. 21 However, despite evidence for the ability of ROS to modify protein SUMOylation, the ability of SUMO to modify ROS levels via the activity of Nox has not been established. Therefore, the goal of the current study was to determine whether Nox enzymes are regulated by protein SUMOylation and to establish a mechanism of action.
Materials and Methods

Cell Culture and Transfection
COS-7 and human aortic vascular smooth muscle cells were cultured and transfected as described previously. 22, 23 human embryonic kidney-293 cells stably expressing Nox5 were transfected with control, SUMO1, and UBC9 small interfering RNA (30 nmol/L, Ambion) using RNAImax (Invitrogen).
Measurement of ROS
Cells were incubated at 37°C with 400 mol/L L-012 (Wako) before the addition of agonists. Luminescence was quantified over time using a Lumistar Galaxy (BMG) luminometer. The specificity of L-012 for ROS was confirmed by transfecting cells with a control plasmid such as green fluorescent protein or lacZ or by coincubation of a superoxide scavenger, such as Tiron (5 mmol/L). 22 
Cell Free Activity Assay
Cells were lysed in MOPS (30 mmol/L, pH 7.2)-based buffer containing KCl (100 mmol/L), Triton (0.3%), and protease inhibitors. Detergent-resistant fractions were resuspended in a PBS buffer containing L-012 (400 mol/L), 1 mmol/L MgCl 2 , 100 mol/L flavin adenine dinucleotide, and 26 mol/L calcium chloride. After a brief period of equilibration, reduced NADPH was injected to a final concentration of 100 mol/L, and the production of ROS was monitored over time.
Measurement of Intracellular Calcium
COS-7 cells were incubated in Hanks' balanced salt solution with 20 mmol/L HEPES and 2.5 mmol/L probenecid. Fluo-4AM (Invitrogen) was used at a final concentration of 4 mol/L with 0.08% Pluronic F-127. Fluorescence was recorded at 485 nm (excitation) and 525 nm (emission) using a BMG Polarstar Omega.
Detection of Protein SUMOylation
Cells were lysed in 50 mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaF, 15 mmol/L Na 4 P 2 O 7 , 1 mmol/L Na 3 VO 4 , 150 mmol/L NaCl, 5 mmol/L EDTA, 15 mmol/L MgCl 2 , 1% nonyl phenoxylpolyethoxylethanol-40, 1% SDS, protease inhibitors, and 20 mmol/L N-ethymaleimide. For polyhistidine-tag purification, cells were lysed in 8 mol/L urea and incubated with Ni-nitriloacetic acid column (Pierce) overnight at 4°C with rocking. HIS-tagged proteins were eluted and immunoblotted for hemagglutinin (HA) or SUMO1.
In Vitro SUMO Conjugation Assays
Immunoprecipitated HA-Nox5 was incubated with 400 nmol/L SAE1/SAE2, 4 mol/L UBC9, 15 mol/L SUMO, and ATP at 30°C for 2 hours (Enzo Life Sciences). Samples were resolved by SDS-PAGE and immunoblotted for SUMO1.
Statistics
All statistical analyses were performed using Instat software and were made using a 2-tailed Student t test or ANOVA with a post hoc test where appropriate. Differences are considered significant at PϽ0.05.
Results
SUMO Negatively Regulates Nox5 Activity
To determine whether SUMO can influence the activity of Nox, SUMO1 and Nox5 cDNA were cotransfected in COS-7 cells, and superoxide release was quantified using L-012 luminescence. SUMO1 potently inhibited both basal ( Figure  1A ) and stimulated Nox5 activity in response to the calciummobilizing agent ionomycin ( Figure 1B ) and the protein kinase C agonist phorbol myristate acetate ( Figure 1C ). SUMO1 inhibited Nox5 activity in a concentration-dependent manner ( Figure 1D ), suggesting that the ability to inhibit Nox5 is directly dependent on the amount of free SUMO1. Increased expression of SUMO1 ( Figure 1A , right) did not decrease Nox5 expression.
Inhibition of ROS Requires the Active Form of SUMO1 and the SUMO-Specific Conjugating Enzyme UBC9 and Is Not Limited to Nox5
The first step in SUMOylation is mediated by C-terminal processing to reveal a diglycine required for substrate conjugation. To determine whether conjugation is necessary for the suppression of ROS by SUMO1, we used a SUMO1 construct that lacks the C-terminal diglycine motif (⌬GG). Loss of the C-terminal glycines prevented the ability of SUMO1 to inhibit Nox5-dependent superoxide production ( Figure 2A ). In contrast, a form of SUMO1 lacking the C-terminal propeptide but containing the C-terminal diglycine motif (hydrolase independent) was as effective as the wild-type (WT) SUMO1, indicating that hydrolysis of the C-terminal tail of SUMO1 is not a rate-limiting step. Other isoforms of SUMO, SUMO2 and the closely related SUMO3 (data not shown), were unable to inhibit Nox5 activity (Figure 2A) .
Following activation by E1 enzymes, SUMO is then transferred to the SUMO-specific E2 conjugating enzyme UBC9, which enables site-specific isopeptide bond formation between SUMO and substrate proteins. 19 To test whether UBC9 is sufficient to promote Nox5 inhibition, we cotransfected Nox5 with active and inactive forms of UBC9 and measured superoxide production. Coexpression of UBC9 with Nox5 resulted in reduced Nox5 activity, whereas a dominant negative lacking a critical catalytic cysteine residue (C93S) was ineffective ( Figure 2B ).
To assess whether SUMO1 can modify the activity of other members of the Nox family, we cotransfected SUMO1 together with Nox1, Nox3, and Nox4 and measured ROS production. SUMO1 was an effective inhibitor of Nox1 ( Figure 2C ), Nox3 ( Figure 2D ), and Nox4 ( Figure 2E ). Importantly, in the absence of transfected Nox enzymes, there was no detectable ROS production from COS-7 cells, and this was unaltered by the presence or absence of SUMO1 ( Figure 2F ). suppressed the expression of SUMO1 and UBC9 in human embryonic kidney-293 cells stably expressing Nox5. Reduced expression of SUMO1 significantly increased Nox5 activity, and superoxide levels were further increased by knockdown of UBC9 ( Figure 3A and 3B). To assess whether endogenous SUMO is important for Nox activity in primary cells, we exposed human neutrophils (a source of Nox2) and human vascular smooth muscle cells (Nox5) to an inhibitor of SUMOylation, anacardic acid. Anacardic acid increased superoxide release from smooth muscle cells and dose-dependently increased superoxide from phorbol myristate acetate-challenged neutrophils ( Figure 3C and 3D ). As shown in Figure 3D (right), exposure of vascular smooth muscle cells to anacardic acid decreased the levels of SUMOylated proteins.
SUMO Directly Influences Nox Activity and Does Not Modify Levels of Intracellular Calcium, Phosphorylation, or Protein Stability of Nox5
We next determined whether SUMO1 directly influences Nox5 activity or secondary events important for activation of Nox5, such as cofactor availability or calcium levels. In an isolated Nox5 activity assay in the presence of supplemental calcium and cofactors (NADPH and flavin adenine dinucleotide), 22 prior expression of SUMO1 strongly suppressed Nox5 activity ( Figure 4A ). SUMO1 did not influence the level of calcium in COS-7 cells ( Figure 4B ), and saturation of intracellular calcium with increasing concentrations of calcium ionophore failed to overcome SUMO1 inhibition (Figure 4C) . A key posttranslational modification that regulates the sensitivity of Nox5 to calcium is via the increased phosphorylation of Thr494 and Ser498. 22 SUMO1 did not modify phorbol myristate acetate-stimulated Nox5 phosphorylation at Thr494 and Ser498 ( Figure 4D ).
In contrast to ubiquitin, the SUMOylation of proteins is not necessarily associated with their degradation. To assess whether SUMO1 influences Nox5 stability, we monitored Nox5 expression following cycloheximide treatment, and SUMO1 did not influence the turnover of Nox5 ( Figure 4E ). In addition, the proteasome inhibitor MG132 was unable to reverse the SUMO1-dependent inhibition of Nox5 ( Figure 4E ).
Coexpression of SUMO1 Does Not Result in the SUMOylation of Nox5
Detection of protein SUMOylation can be technically demanding, 24 and to determine whether Nox5 is a substrate for SUMOylation, we adopted a number of approaches. First, as a positive control, we cotransfected a known target of SUMO, myc-tagged BMAL1 (ARNTL), 25 with HA-SUMO1 or enhanced yellow fluorescent protein (EYFP)-SUMO1. As shown in Figure 5A , in the presence of SUMO, additional species of BMAL1 were observed that were approximately 10 and 40 kDa higher in molecular weight (see arrows), corresponding to the addition of HA-SUMO and EYFP-SUMO, respectively. In a parallel experiment with Nox5, we again observed a greatly diminished ability of Nox5 to generate ROS in the presence of HA-SUMO1 and EYFP-SUMO1 ( Figure 5B ), but we did not consistently observe higher molecular weight species consistent with SUMOylation as shown for BMAL1. To improve sensitiv- ity, we coexpressed a HIS-tagged SUMO1 with Nox5 and purified HIS-tagged proteins using Ni-nitriloacetic acid affinity columns. The coexpression of Nox5 with HIS-SUMO1 did not result in the detection of additional, higher molecular weight species of Nox5 ( Figure 5D ). However, we did observe a substantial concentration of other HIS-SUMOylated proteins ( Figure 5E) . To yet further enhance sensitivity, we constructed a fusion-protein consisting of the SUMO-specific conjugating enzyme UBC9 attached to the N-terminus of Nox5. This approach has been shown to promote robust SUMOylation of other substrates. 26 We cotransfected WT and UBC-Nox5 with HIS-SUMO1 and EYFP-SUMO1 and measured both ROS production and protein expression. As shown in Figure 5F , HA-SUMO1 and EYFP-SUMO1 significantly reduced ROS production from both WT Nox5 and the UBC9-Nox5 fusion protein. However, we could not detect evidence of SUMOylation of Nox5 with either the WT or the fusion protein ( Figure 5G ).
To examine whether Nox5 can be SUMOylated in vitro, we incubated immunoprecipitated HA-Nox5 with recombinant SUMO1, E1-activating (SAE1/SAE2), and E2-conjugating (UBC9) enzymes. In the presence of ATP, Nox5 appears to be SUMOylated, as evidenced by higher molecular weight bands that are immunoreactive to SUMO1 (Supplemental Figure  I , available online at http://atvb.ahajournals.org). The SUMOylation of RANGAP1 (Supplemental Figure I , upper band on right) was used as a positive control. We also generated other fusion proteins, including UBC9-SUMO1, which has improved ability to SUMOylate substrates and was more effective at inhibiting Nox5 activity versus SUMO1 alone (Supplemental Figure IIA) . The direct fusion of SUMO1 with Nox5 also produced interesting results, with the SUMO1-Nox5 fusion product producing dramatically less superoxide in comparison with the WT-Nox5. In contrast, fusion of SUMO1 (⌬GG) that could not be conjugated to substrates with Nox5 did not reduce ROS production. The fusion of SUMO1 to Nox5 resulted in the detection of several higher molecular weight species of Nox5, but these are unlikely to be due to polySUMOylation (Supplemental Figure IIB) .
Mutation of Predicted Sites of SUMOylation and Conserved Lysines on Nox5 Fail to Prevent the Inhibition of ROS Production
Despite clear evidence that SUMO inhibits Nox5 activity, we could not detect the SUMOylation of Nox5. However, technical difficulties inherent in detecting SUMOylated proteins 24 may be further compounded by the difficulties extracting and immunoblotting Nox. 22 Indeed, the ability to SUMOylate Nox5 in an in vitro reaction suggests that the SUMOylation of Nox5 could be possible in cells, and the direct fusion of SUMO1 with Nox5 suggests that when SUMO1 is attached to Nox5 it suppresses enzyme activity. Therefore, to exclude the possibility that Nox5 SUMOylation was occurring but could not be detected, we next adopted a loss of function approach by mutating select lysine residues to arginine. There are 2 predicted SUMO attachment sites on Nox5 at lysines 119 and 636 (SUMOsp2.0) out of 37 total lysine residues (Nox5␤) that are extremely well conserved across species. However, mutation of these sites to arginine did not prevent the inhibition of Nox5 activity by SUMO1 ( Figure  6 ). To exclude other lysine residues that may not conform to established SUMO motifs, we mutated other conserved lysine residues and assessed whether they prevented Nox5 inhibition.
As shown in Figure 6 , mutation of more than 19 lysine residues failed to reverse the inhibitory effects of SUMO1. We also assessed whether recombinant SUMO proteins could directly modify Nox5 activity in an isolated activity assay. We found that neither active forms of recombinant SUMO1 nor SUMO2 or SUMO3 had direct inhibitory actions on Nox5 (Supplemental Figure III) .
Discussion
The present study identifies SUMOylation as a novel mechanism that negatively regulates the activity of the Nox and limits the production of ROS. We found that SUMO1 can potently reduce ROS production from Nox1 to Nox5 and that the active forms of SUMO1 and the SUMO-specific conjugating enzyme UBC9 are required to suppress ROS production. Furthermore, inhibition of endogenous SUMOylation using small interfering RNA or a pharmacological inhibitor increases ROS production from human vascular smooth muscle cells and neutrophils and suggests that SUMO is an endogenous suppressor of ROS production. The overproduction of ROS by Nox enzymes is a fundamental mechanism underlying the vascular dysfunction associated with cardiovascular disease and excessive inflammation. 9 Aside from changes in the expression level of the various subunits, Nox activity is controlled through posttranslational modifications. 11 Nox5 is unique among the Nox isoforms in that its activity does not depend on the binding of additional proteins. Instead, the regulatory elements controlling Nox5 activity are contained within 1 protein and thus posttranslational changes in the activity of Nox5 are likely to be due to modifications specific to Nox5 and not other proteins or subunits. For these reasons, we used Nox5 as a surrogate to explore the mechanisms by which SUMO inhibits Nox activity. We found that only SUMO1, but not SUMO2 or the closely related SUMO3, was able to inhibit Nox5. This is consistent with previous reports that paralogs of SUMO exhibit significant substrate specificity. For example, RANGAP1 is preferentially modified by SUMO1 and topoisomerase II by SUMO2/3. 3, 27 The ability of SUMO1 to suppress Nox5 activity in an isolated activity assay that separates Nox5 from cytosolic variables, including other proteins, calcium, NADPH, and flavin adenine dinucleotide levels, strongly suggests a direct effect of SUMO1 on Nox activity. Importantly, SUMO did not decrease the expression or turnover of Nox5, and the reduced production of ROS could not be reversed by inhibitors of the proteasome, which further supports a posttranslational mechanism. As Nox5 activity is strongly dependent on calcium availability, we also investigated whether SUMO1 affects the concentration of intracellular calcium or the sensitivity of Nox5 to calcium, which is mediated via phosphorylation of Thr494 and Ser498. 22 We found that SUMO did not affect the level of intracellular calcium or Nox5 phosphorylation and the ability of SUMO to reduce Nox5 activity in an isolated enzyme assay also rules out changes in subcellular localization as a primary mechanism of inhibition. 28 Recombinant SUMO1 protein did not directly inhibit Nox5 enzyme activity, and a form of SUMO1(⌬GG) that cannot be conjugated to substrates failed to inhibit Nox5, suggesting that Nox5 is directly modified by SUMO1. However, we could not find evidence of Nox5 SUMOylation and mutational analysis of 19 predicted SUMO sites (KxE, where is a bulky hydrophobic residue and x is any residue 29 ) and other conserved lysine residues did not reveal a functionally significant attachment site for SUMO modification. Direct fusion of WT but not ⌬GG SUMO1 with Nox5 resulted in enzyme inhibition and the appearance of multiple higher molecular weight species of Nox5, but it is unlikely that this reflects polySUMOylation. Thus, we must exclude direct SUMOylation of Nox5 as a mechanism of inhibition. We found that SUMO1 inhibited the activities of Nox1, Nox3, and Nox4, in addition to the activity of Nox5. In neutrophils in which the predominant oxidant producing enzyme is Nox2, 30 a pharmacological inhibitor of endogenous SUMOylation, anacardic acid, 31 increased ROS production, suggesting that SUMOylation also represses the activity of Nox2. Similarly, in human vascular smooth muscle cells expressing Nox5, inhibition of SUMOylation potentiates superoxide production and provides further evidence that endogenous SUMO represses Nox activity to limit ROS production. However, comparison of the amino acid sequence of Nox5 with that of Nox1 to Nox4 reveals little evidence for the existence of conserved SUMOylation motifs or lysine residues that would provide a common mechanism for Nox inhibition. Other than direct SUMOylation, other potential mechanisms by which SUMO1 could inhibit Nox activity is via altered protein-protein interactions via a noncovalent SUMO interacting motif (Ser-X-Ser), 32 which can orchestrate protein-protein interactions with other proteins that are SUMOylated. In addition, SUMO1 has been shown to SUMOylate superoxide dismutase-1, which promotes increased protein stability. However, this mechanism cannot explain the ability of SUMO1 to inhibit Nox5 in an isolated enzyme assay or Nox4, which emits primarily hydrogen peroxide. We recently described the ability of mitogen-activated protein kinase kinase-1 to regulate Nox5 activity via extracellular-signal-regulated kinases-1/ 2, 33 and the SUMOylation of mitogen-activated protein kinase kinase-1 34 could indirectly influence Nox5 activity. Evidence against this is the lack of change in Nox5 phosphorylation in the presence of SUMO1 and ability of SUMO1 to inhibit other Nox enzymes, such as Nox4, that are not regulated by mitogen-activated protein kinase kinase-1. Alternatively, as the majority of SUMO substrates are transcription factors, 35 it is possible that changes in the expression level of other proteins could conspire to suppress Nox activity. One pertinent example is the SUMOylation and inhibition of the transcription factor pleomorphic adenoma gene-like 2, which has been shown to regulate expression of the Nox subunit p67phox. 36 However, this could not influence Nox4 or Nox5 activity or even Nox1/Nox3 in the presence of NOXO1 and NOXA1. Further identification of novel mechanisms is likely to be a complex endeavor and is beyond the scope of the present study. SUMOylation is an important mechanism for the posttranslational regulation of protein function; it can influence transcription, intracellular localization, protein-protein interactions, and cell signaling. 37, 38 The mechanisms controlling protein SUMOylation are poorly understood, and cellular stresses in the form of heat, osmotic pressure, genotoxic insults, and ROS 3, 4 have all been shown to promote SUMOylation. SUMOylation provides protection against thermal and ischemic damage in hibernating animals 5 and is increased in a number of disease states, including Parkinson disease, Huntington disease, diabetes, and cancer. 39 Although the sum effect of increased SUMOylation is thought to be cytoprotective, the effect of SUMO on individual proteins is likely to vary considerably. In this study, the SUMOylation of Nox enzymes and the resulting reduction in ROS would be consistent with a protective mechanism that limits further cellular damage from excessive ROS formation. However, not all of the effects of SUMOylation are protective. The increased SUMOylation of extracellular-signal-regulated kinases-5 reduces its transcriptional activity and exacerbates deficits in cardiac function induced by myocardial ischemia, 20 and the SUMOylation of transglutaminase promotes inflammation. 40 ROS in the form of hydrogen peroxide can dramatically increase protein SUMOylation. 3 However, the effect of ROS and oxidative stress on protein SUMOylation is complex. The amount of ROS is a very important variable, and high concentrations of hydrogen peroxide (in the millimolar range) have been shown to promote SUMOylation, whereas low concentrations decrease overall SUMOylation. Low concentrations of hydrogen peroxide preferentially oxidize the catalytic cysteine residues of the SUMO conjugating enzymes and reduce SUMOylation. In contrast, higher concentrations inactivate the SUMO isopeptidases that deconjugate SUMO, resulting in increased SUMOylation. 21 The influence of endogenously produced ROS is likely to add to this complexity. Inside the cell, ROS production occurs at discrete intracellular sites, 16, 41, 42 and the local concentration of ROS may vary considerably with location and thus may selectively influence the SUMOylation of proximal proteins. Indeed, even comparatively large concentrations of extracellular ROS fail to promote uniform changes in the SUMOylation/deSUMOylation of substrates. 21 Although we have shown that inhibition of endogenous SUMOylation can potentiate ROS output in neutrophils and smooth muscle cells, it remains to be determined whether ROS production itself controls the degree of protein SUMOylation and inhibition of Nox enzymes or whether other cellular stresses participate.
In summary, we have shown that SUMO1 suppresses the activity of the Nox enzymes and reduces ROS production. Inhibition of SUMOylation potentiates ROS production, suggesting that endogenous SUMO1 controls ROS output. However, we did not find evidence to support the concept that Nox enzymes are direct substrates for SUMO conjugation. Further studies are necessary to elucidate the mechanisms by which SUMOylation affects the activity of the Nox enzymes and to determine the importance of this pathway in diseases associated with the overproduction of ROS.
